177Lu-PSMA-617治疗中基于单次治疗后SPECT/CT扫描的辐射剂量学:一种生成时间与组织特异性剂量因子的新方法
该研究提出一种简化剂量估算方法,通过将已有时间-放射性曲线归一化至单次测量时间,生成177Lu-PSMA-617治疗中肿瘤及正常组织的单时间点剂量转换因子,并评估其与系列显像方案相比的附加不确定度。肿瘤剂量因子在24、48、72、96小时分别为11.0、12.1、13.6、15.2 Gy每MBq/mL;腮腺和肾脏因子也随成像时间延长而升高。肿瘤剂量估算在72小时后延迟扫描最准确,健康组织剂量在治疗前2天扫描表征最佳。
要点
- 单次治疗后SPECT/CT可估算177Lu-PSMA-617的辐射剂量。
- 肿瘤剂量因子在24、48、72、96小时分别为11.0、12.1、13.6、15.2 Gy每MBq/mL。
- 肿瘤剂量估算在72小时后延迟扫描最准确,健康组织剂量在治疗前2天扫描表征最佳。
核心结论
- 该工作展示了一种在177Lu-PSMA-617治疗中高效估算剂量的方法,通过简化并可能自动化辐射剂量学,希望加速对该治疗背景下放射生物学的理解及剂量-反应模型的开发。
研究设计与样本
- 本研究为技术描述性工作,提出简化剂量估算方法,并将其应用于转移性前列腺癌的177Lu-PSMA-617治疗评估。
- 通过将已有时间-放射性曲线归一化至单次测量时间,计算与吸收辐射剂量相关的时间积分活度均值和范围。
- 为辅助训练队列的准确药代动力学建模,开发了一种轮廓引导的图像配准方法。
主要发现
- 报告了常见治疗后成像时间的组织特异性剂量转换因子,并表征了与传统系列显像方案相比的附加不确定度。
- 肿瘤的单时间点剂量因子在成像时间24、48、72、96小时分别为11.0、12.1、13.6、15.2 Gy每MBq/mL。
- 正常组织中,腮腺在上述时间的因子分别为6.7、9.4、13.3、19.3 Gy每MBq/mL,肾脏分别为7.1、10.3、15.0、22.0 Gy每MBq/mL。
- 肿瘤剂量估算在72小时之后的延迟扫描最为准确。
- 健康组织剂量因早期示踪剂清除程度较大,在治疗前2天扫描患者时表征最佳。
关键数值与推荐
- 肿瘤单时间点剂量因子:24小时11.0 Gy每MBq/mL,48小时12.1 Gy每MBq/mL,72小时13.6 Gy每MBq/mL,96小时15.2 Gy每MBq/mL。
- 腮腺单时间点剂量因子:24小时6.7 Gy每MBq/mL,48小时9.4 Gy每MBq/mL,72小时13.3 Gy每MBq/mL,96小时19.3 Gy每MBq/mL。
- 肾脏单时间点剂量因子:24小时7.1 Gy每MBq/mL,48小时10.3 Gy每MBq/mL,72小时15.0 Gy每MBq/mL,96小时22.0 Gy每MBq/mL。
- 肿瘤剂量估算最准确的条件为72小时之后的延迟扫描。
- 健康组织剂量表征最佳的条件为治疗前2天内扫描。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Calculation of radiation dosimetry in targeted nuclear medicine therapies is traditionally resource-intensive, requiring multiple posttherapy SPECT acquisitions. An alternative approach is to take advantage of existing pharmacokinetic data from these smaller cohorts to enable dose computation from a single posttreatment scan in a manner that may be applied to a much broader patient population. Methods: In this work, a technical description of simplified dose estimation is presented and applied to the assessment of 177Lu-prostate-specific membrane antigen (PSMA)-617 therapy for metastatic prostate cancer. By normalizing existing time-activity curves to a single measurement time, it is possible to calculate a mean and range of time-integrated activity values that relate to absorbed radiation dose. To assist with accurate pharmacokinetic modeling of the training cohort, a method for contour-guided image registration was developed. Results: Tissue-specific dose conversion factors for common posttreatment imaging times are reported along with a characterization of added uncertainty in comparison to a traditional serial imaging protocol. Single-time-point dose factors for tumor were determined to be 11.0, 12.1, 13.6, and 15.2 Gy per MBq/mL at image times of 24, 48, 72, and 96 h, respectively. For normal tissues, parotid gland factors were 6.7, 9.4, 13.3, and 19.3 Gy per MBq/mL at those times, and kidneys were 7.1, 10.3, 15.0, and 22.0 Gy per MBq/mL. Tumor dose estimates were most accurate using delayed scanning at times beyond 72 h. Dose to healthy tissues is best characterized by scanning patients in the first 2 d of treatment because of the larger degree of tracer clearance in this early phase. Conclusion: This work demonstrates a means for efficient dose estimation in 177Lu-PSMA-617 therapy. By providing methods to simplify and potentially automate radiation dosimetry, we hope to accelerate the understanding of radiobiology and development of dose-response models in this unique therapeutic context.
引用
- Jackson PA, Hofman MS, Hicks RJ, et al. Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. J Nucl Med. 2019. PMID: 31806772. doi:10.2967/jnumed.119.233411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。